Genomic profiling review uncovers drivers of disease evolution in myeloproliferative neoplasms, highlighting biomarkers that predict long-term clinical stability.
We provide an overview of a recent study in Cancer Discovery by Leongamornlert and colleagues involving genomic profiling of 30 patients with myeloproliferative neoplasms using available blood or bone marrow samples to assess what factors underlie disease evolution or predict stability. See related article by Leongamornlert et al., p. 1843.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: